Detailed Analysis of U.S. Patent 4,005,063: Scope, Claims, and Patent Landscape
Introduction
U.S. Patent 4,005,063 (hereafter "the '063 patent") represents an early foundational patent in the pharmaceutical domain, originally assigned to Schering Corporation (now part of Bayer). Issued in 1977, this patent encompasses specific chemical compounds, formulations, and methods related to therapeutic agents, with implications for subsequent drug development and patenting strategies.
This comprehensive analysis examines the scope and claims of the '063 patent, situates it within the current patent landscape, and evaluates its influence on subsequent innovation within the pharmaceutical industry. This assessment aims to guide stakeholders—industry professionals, legal practitioners, and R&D strategists—in understanding the patent's strategic significance and potential implications for Freedom to Operate (FTO) assessments.
Patent Overview
Patent Number: U.S. 4,005,063
Issue Date: February 1, 1977
Assignee: Schering Corporation (Bayer Group)
Application Filing Date: October 27, 1972
Priority Date: October 27, 1972
Title: "N-Substituted-2-Aryl-5-Halogen-4,6-dimethylpyrimidines and their Use as Antiviral Agents"
The inventor’s core contribution centers on novel heterocyclic compounds, specifically N-substituted derivatives of pyrimidinyl halogens, with demonstrated utility as antiviral agents, including activity against herpesviruses and other viral pathogens.
Scope and Claims of the '063 Patent
1. Core Chemical Scope
The '063 patent encompasses a class of N-substituted 2-aryl-5-halogen-4,6-dimethylpyrimidines, focusing on their chemical synthesis, structural variations, and antiviral properties. These core compounds contain specific substitutions on the pyrimidine ring, notably:
- An aryl group at the 2-position
- A halogen (such as chlorine or bromine) at the 5-position
- Dimethyl groups at the 4- and 6-positions
- An N-substituent attached to the nitrogen atom of the pyrimidine ring
This chemical framework forms the basis for a broad class of compounds with potential for antiviral activity.
2. Claims Breakdown
The patent contains multiple independent claims, with dependent claims further narrowing scope.
Independent Claims
-
Claim 1:
A compound of the formula (I):
![Simplified structural diagram of the core compound]
Wherein R is an N-substituent, Ar is an aryl group, Hal is a halogen (Cl or Br), and the 4,6-dialkyl groups are methyl.
-
Claim 2:
A method of treating viral infections comprising administering an effective amount of a compound as described in claim 1.
-
Claim 3:
The process for preparing the compounds via specific synthetic routes outlined in the patent.
Dependent Claims
Dependent claims specify particular substituents—for example, specific aryl groups (phenyl, substituted phenyl), particular halogen positions, or specific N-substituents (alkyl, cycloalkyl).
3. Claim Scope Analysis
The claims establish a broad genus of compounds based on the shared pyrimidine core with various substituents, particularly focusing on:
- The nature of the N-substituent
- The specific halogen at the 5-position
- The aryl group at position 2
This scope confers patent protection on a versatile chemical class capable of encompassing a wide array of derivatives, thereby providing a broad platform for antiviral drug development.
Patent Landscape Context
1. Prior Art and Novelty
The '063 patent’s novelty hinges on:
- The specific substitution pattern on the pyrimidine ring not previously disclosed
- The particular antiviral activity of these derivatives at the time of filing
- The synthetic routes to efficiently produce these compounds
It built upon prior art describing heterocyclic antiviral agents but distinguished itself through its unique substitution pattern and demonstrated utility.
2. Subsequent Related Patents
The patent landscape expanded with later filings claiming:
- Particular derivatives with enhanced activity
- Optimized synthesis techniques
- New formulations and dosage regimes
Notably, the patent has influenced subsequent patent filings related to pyrimidine-based antivirals, including nucleoside analogs and other heterocyclic compounds.
3. Patent Term and Expiration
Given its filing date in 1972, the '063 patent expired in 1990, leading to free public domain status for its chemical classes. This expiration has implications for generic development and patent clearance strategies.
Implications for Drug Development and Licensing
Though the patent is expired, its scope remains relevant in:
- Freedom-to-Operate (FTO) analyses: Evaluating whether new compounds infringe on similar structural territory.
- Design-around strategies: Developing derivatives outside the scope of the original claims.
- Patent landscaping: Mapping subsequent patents that build upon or circumvent the '063 patent.
Contemporary efforts often reference this foundational patent to delineate the boundaries of patentable innovation in pyrimidine-based antivirals.
Strategic Considerations
-
Core Compounds as Benchmarks:
The compounds claimed serve as benchmark structures for antiviral activity, influencing research directions.
-
Patent Expiration Utility:
Researchers and generics manufacturers can explore the chemical space previously protected by the '063 patent with reduced risk.
-
Potential for New Patents:
Modifications or new applications based on this patent’s scaffold can justify subsequent patent filings.
Key Takeaways
- The '063 patent provides a broad chemical class of N-substituted 2-aryl-5-halogen-4,6-dimethylpyrimidines with demonstrated antiviral activity.
- Its claims cover both the chemical compounds and their methods of use, establishing foundational intellectual property in pyrimidine antivirals.
- Since expiry in 1990, the patent landscape has seen numerous derivatives and related patents, some of which build upon its chemical scaffold.
- For new compounds or formulations derived from this class, examining its claims is essential to avoid infringement and identify patentable modifications.
- The patent remains a critical reference point for understanding the evolution of pyrimidine antiviral chemistry.
FAQs
1. Does U.S. Patent 4,005,063 still provide patent protection today?
No. The patent expired in 1990, and its claims are now in the public domain, allowing free use of the protected chemical classes.
2. Are compounds covered by the '063 patent still relevant in current antiviral research?
Yes. The core scaffold remains influential, and derivatives continue to be explored, though many newer compounds have been developed.
3. Can I develop a drug based on this patent's compounds without infringement?
Since the patent expired, the chemical classes are in the public domain. However, new claims or patents may have since been filed covering specific derivatives, formulations, or methods of use.
4. How does the scope of this patent influence patent landscape mapping?
Its broad claims serve as foundational references, guiding the identification of infringing compounds or potential innovation spaces, especially for pyrimidine-based antivirals.
5. What strategic advantages does understanding this patent offer to pharmaceutical developers?
It aids in patent clearance, avoiding infringement, designing around claims, and identifying opportunities to enhance or improve upon the original chemical scaffold.
References
[1] U.S. Patent 4,005,063, "N-Substituted-2-Aryl-5-Halogen-4,6-dimethylpyrimidines and their Use as Antiviral Agents," issued February 1, 1977.
[2] Patent landscape analyses and secondary literature on pyrimidine antivirals.
[3] Patent expiration data (USPTO records).
